PURPOSE: The epidermal growth factor receptor inhibitors, gefitinib and erlotinib, are used
as standard salvage therapy for advanced non-small-cell lung cancer (NSCLC). The aim of …

PURPOSE: Gefitinib and erlotinib are potent EGFR TKIs, with antitumor activity. In this
randomized, single-center, non-comparative phase II trial, the efficacy and safety of gefitinib …

Introduction: Epidermal growth factor receptor-tyrosine kinase inhibitors are used as
effective first-line and salvage therapy in the treatment of advanced non-small cell lung …

BACKGROUND: Gefitinib and erlotinib are commonly used for salvage therapy in patients
with nonsmall cell lung cancer (NSCLC) who have progressed on prior therapies. Although …

7551 Background: Gefitinib and erlotinib are potent inhibitors of the epidermal growth factor
receptor tyrosine kinase (EGFR TK), with single agent antitumor activity. In this randomized …

Purpose To evaluate the efficacy and safety of erlotinib in advanced non-small-cell lung
cancer after failure of gefitinib treatment. Patients and methods Patients with advanced or …

Purpose Chemotherapy is the mainstay treatment for advanced non-small cell lung cancer
(NSCLC). Gefitinib, an epidermal growth factor receptor—tyrosine kinase inhibitor (EGFR …

Background: The epidermal growth factor receptor tyrosine kinase inhibitors gefitinib and
erlotinib are effective for advanced non-small cell lung cancer (NSCLC). This meta-analysis …

Among treatment modalities for lung cancer, the most promising therapy is the use of
epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs). Both erlotinib and …

Background: Erlotinib and gefitinib are epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs). They have the same mechanism of action and very similar side …